RA
Reinhard Ambros
Board Of Directors at Genedata
Basel, Basel
Overview
Reinhard Ambros is the Chairman of the Board at ImmunOs Therapeutics AG, with a background in the pharmaceutical industry and biotechnology. He has held prominent roles at Novartis, including Head of Novartis Venture Funds and Head of Novartis Group Strategy, showcasing expertise in corporate development and venture capital within the life sciences sector.
Ambros has a strong track record of serving on the Board of Directors for various companies such as Genedata, Viridos, and Aileron Therapeutics, and has made significant investments in companies like ImmunOs Therapeutics and FORMA Therapeutics, demonstrating a keen eye for successful ventures in the pharmaceutical and biotech industries.
Work Experience
Board Of Directors
2006 - Current
Board Of Directors
2018
Board Of Directors
2013
Board member Aileron Therapeutics
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides.
Raised $256,212,894.00 from Nantahala Capital Management and Bios Partners.
Board Of Directors
2019
TruDataRx uses clinical data to help clients improve clinical efficacy and reduce the costs of pharmacy benefits for its members.
Raised $275,010.00.
Chairman of the Board of Directors
2019
Board Of Directors
2018 - 2024
Chairman of the Board of Directors
2019 - 2023
Chairman Of The Board
2019 - 2022
Head Novartis Venture Funds
2005 - 2018
Built the Novartis Venture Fund and management team to one of the largest and most active corporate venture fund in life sciences with about 1 bn$ under management.
Head Novartis Group Strategy
2001 - 2004
Develop the Novartis group strategy
Head BD&L for Cardiovascular and Metabolism
1999 - 2001
Leading in/out licensing projects